Swedish company Cantargia has enrolled the first patient in the Phase Ib/IIa trial of nadunolimab for treating individuals with acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS).

Dr. Petri Bono, Chief Medical Officer of Faron Pharmaceuticals, said:"Patients with relapsed or refractory high-risk MDS have very limited treatment options, and the need for novel, effective ...